Clinical features of adenoma patients and adenocarcinoma patients
| Patient number | Sex | Age | Pathology | MPEF/Cu/normal tissue | MPEF/Cu/tumour | MPEF/Zn/normal | MPEF/Zn/tumour |
| 1 | M | 62 | TA, LGD | 114.5±39.7 | 193.8±5.8 | 174.5±33.1 | 84.9±8.8 |
| 2 | F | 61 | TA, HGD | 258.3±15.4 | 487.4±8.8 | 233.6±12.7 | 112.3±22.6 |
| 3 | M | 63 | TA, LGD | 128.3±17.9 | 234.9±13.6 | 197.9±23.8 | 111.3±14.1 |
| 4 | F | 76 | TA, LGD | 83.4±11.9 | 201.3±17.5 | 221.1±11.3 | 119.2±14.6 |
| 5 | M | 68 | Adenoca. Poor diff. (T4N2M0) | 104.6±17.9 | 239.8±4 | 153.7±23.9 | 96.2±20.8 |
| TA, LGD | 208.1±13.5 | 105.5±15.3 | |||||
| 6 | M | 70 | Adenoca. moderate diff. (T3N0M0) | 167.0±20.2 | 245.7±10.5 | 189.6±39.0 | 89.2±19.6 |
| TA, LGD | 230.9±5.2 | 109.1±19.4 | |||||
| 7 | M | 76 | Adenoca. moderate diff. (T3N0M0) | 99.7±11.8 | 213.1±19.0 | 217.1±16.9 | 120.6±17.3 |
| 8 | M | 65 | TA, LGD | 85.9±15.2 | 216.8±11.1 | 217.1±16.9 | 120.6±17.3 |
| 9 | F | 55 | TA, LGD | 100.6±23.5 | 173.0±32.5 | 174.2±17.3 | 122.7±18.8 |
| 10 | M | 69 | Adenoca. well diff. (T1N0M0) | 108.9±9.9 | 228.5±14.3 | 191.4±17.9 | 105.9±14.2 |
| 11 | M | 58 | Serrated adenoma, LGD | 113.3±19.9 | 224.5±18.9 | 190.4±17.9 | 114.7±14.4 |
| 12 | F | 70 | TA, LGD | 119.7±15.6 | 207.3±13.3 | 174.8±22.4 | 113.9±16.9 |
| 13 | F | 50 | Adenoca. well diff. (T1N0M0) | 101.9±19.6 | 193.0±15.3 | 180.5±12.6 | 108.9±15.0 |
| 16 | F | 41 | Adenoca. moderate diff. (T2N0M0) | 95.4±12.6 | 195.9±22.1 | 211.1±22.4 | 95.3±17.6 |
| 17 | M | 53 | Adenoca. moderate diff. (T4N1M0) | 94.5±26.7 | 210.3±24.7 | 199.6±18.9 | 109.2±16.5 |
| TA, LGD | 179.9±16.4 | 101.7±16.8 |
MPEF, multi-photon excited fluorescence; TA, tubular adenoma; LGD, low-grade dysplasia; HGD, high-grade dysplasia; NA, not available.